Doctors are pulling back on prescribing finasteride and dutasteride — drugs sold under brand names like Proscar, Avodart, and Propecia — because mounting evidence links these medications to serious psychiatric harm, including depression and suicidal ideation. In August 2022, the FDA added suicidal ideation and behavior as an adverse reaction to finasteride’s label, a move that came only after five years of pressure from a citizen petition requesting a black-box warning. For a drug class originally considered relatively benign, that label change sent a clear signal to prescribers: the risk calculus has shifted.
These medications belong to a class called 5-alpha reductase inhibitors, or 5-ARIs, which work by blocking the conversion of testosterone to dihydrotestosterone (DHT). They are prescribed for enlarged prostate (benign prostatic hyperplasia) and, at lower doses, for male pattern hair loss. But the emerging picture — one that includes persistent sexual dysfunction, potential masking of prostate cancer during screening, and a troubling pattern of psychiatric adverse events in younger men — has made many clinicians far more cautious about reaching for the prescription pad. This article breaks down the specific warnings, the research driving the shift, and what patients and caregivers should know, particularly those already managing cognitive or neurological concerns.
Table of Contents
- What Made Doctors Rethink This Common Prostate Drug?
- Post-Finasteride Syndrome and Why Stopping the Drug Does Not Always Fix the Problem
- The Prostate Cancer Screening Problem That Changed the Conversation
- What Patients Should Discuss With Their Doctor Before Starting or Continuing a 5-ARI
- Telehealth Prescribing and the Informed Consent Gap
- Legal Fallout and What It Signals About the Drug’s Risk Profile
- Where the Science and Regulation Are Heading
- Conclusion
- Frequently Asked Questions
What Made Doctors Rethink This Common Prostate Drug?
The turning point was not a single study but a convergence of regulatory action, adverse event data, and independent research. An analysis of the FDA Adverse Event Reporting System found that suicidality signals associated with finasteride peaked in 2022, with a reported odds ratio of 34.64 — meaning reports of suicidal thoughts and behavior were dramatically overrepresented among finasteride users compared to other drugs in the database. The signal remained alarmingly high in surrounding years as well, with an odds ratio of 33.72 in 2021 and 30.53 in 2023. These are not numbers that can be easily dismissed as background noise. Young patients appear to be at particular risk.
FDA data show that men between ages 18 and 44 experienced higher rates of suicidality and psychological adverse events while taking finasteride. This matters because younger men are often prescribed the drug for hair loss — a cosmetic indication — making the risk-benefit conversation fundamentally different from treating an older man with a significantly enlarged prostate causing urinary obstruction. A doctor weighing quality-of-life improvement against potential psychiatric harm will reach a very different conclusion depending on who is sitting across the exam table. In October 2025, a study from the Hebrew University of Jerusalem, published in the Journal of Clinical Psychiatry, added further weight to these concerns. The researchers found that finasteride users experience significantly higher rates of depressive symptoms and posed a pointed question in their findings: “Why are we still ignoring the suicide risk?” For clinicians who had been on the fence, that study — from a respected institution, in a major journal — made it harder to prescribe without a serious conversation about mental health.
Post-Finasteride Syndrome and Why Stopping the Drug Does Not Always Fix the Problem
One of the most unsettling aspects of finasteride’s risk profile is a condition known as Post-Finasteride Syndrome, or PFS. This is not simply a matter of side effects that resolve once the medication is discontinued. PFS is characterized by persistent sexual dysfunction and neuropsychiatric symptoms that continue long after a patient stops taking the drug — in some cases, indefinitely. The data on sexual side effects are particularly stark. Research shows that one-third of men who developed new erectile dysfunction while taking finasteride continued to experience ED more than 90 days after stopping the drug. Some men who used finasteride became infertile.
For a patient population that may already be dealing with age-related health changes, the prospect of adding irreversible sexual dysfunction is a serious clinical concern. However, it is important to note that not every patient will develop PFS, and the condition remains difficult to predict in advance. There is currently no reliable way to identify who is most vulnerable before prescribing. For families and caregivers in the dementia and brain health space, PFS raises an additional flag. Neuropsychiatric symptoms — depression, cognitive fog, anxiety — overlap with early signs of cognitive decline. If an older adult is taking finasteride and begins showing mood or memory changes, there is a real risk that those symptoms could be attributed to aging or early dementia rather than the medication. This is a diagnostic pitfall that deserves attention in any comprehensive care plan.
The Prostate Cancer Screening Problem That Changed the Conversation
Beyond mental health, the FDA updated its warnings for all 5-ARIs to note that these drugs may increase the risk of high-grade prostate cancer. In clinical trials, finasteride 5mg was associated with a 1.8% incidence of high-grade cancer (Gleason score 8–10) compared to 1.1% for placebo. Dutasteride showed a similar pattern: 1.0% versus 0.5%. However, the full story is more complicated — and arguably more concerning in a different way. The Prostate Cancer prevention Trial showed that finasteride reduced overall cancer detection by 20%, and the REDUCE trial found dutasteride reduced it by 23%. That sounds like good news until you understand the mechanism: 5-ARIs cause roughly a 50% drop in PSA levels.
PSA testing is one of the primary screening tools for prostate cancer. When PSA is artificially suppressed by a medication, cancers that would normally be caught during routine screening can be missed entirely. The drug does not prevent cancer — it masks it. More recent large population-based studies suggest the apparent increase in high-grade cancer may actually be a detection artifact rather than a true biological increase in aggressive tumors. The theory is that 5-ARIs shrink benign prostate tissue, making existing high-grade cancers more detectable on biopsy relative to overall prostate volume. Despite this more reassuring interpretation, the FDA label warning remains in place, and clinicians must account for it. The practical takeaway is this: if a patient is on a 5-ARI, his PSA values cannot be interpreted at face value, and both the patient and his doctor need to adjust screening expectations accordingly.
What Patients Should Discuss With Their Doctor Before Starting or Continuing a 5-ARI
The first and most important step is an honest conversation about the reason for the prescription. A man with severe urinary symptoms from an enlarged prostate — difficulty urinating, frequent nighttime urination, risk of urinary retention — faces a different risk-benefit equation than a man using the same drug class for thinning hair. For the former, the functional benefits may outweigh the risks when other options have failed. For the latter, the calculus tips sharply the other way now that psychiatric risks are on the label. Patients should ask about alternatives.
Alpha-blockers such as tamsulosin (Flomax) work through a different mechanism and do not carry the same psychiatric or cancer-screening concerns, though they have their own side effect profile, including dizziness and retrograde ejaculation. Minimally invasive procedures like UroLift or Rezum have become viable options for many men with enlarged prostates, offering symptom relief without chronic medication. For hair loss, minoxidil (Rogaine) works topically without the systemic hormonal effects of finasteride, though it is generally considered less effective for certain hair loss patterns. Anyone already on a 5-ARI should not stop abruptly without medical guidance, but they should bring these concerns to their next appointment. If a patient or family member notices new depression, anxiety, sleep disturbances, or sexual dysfunction after starting the medication, these should be reported to a physician immediately — not assumed to be unrelated.
Telehealth Prescribing and the Informed Consent Gap
A newer dimension of this issue involves the telehealth boom. As of March 2025, investigations are underway into telehealth companies like Hims, Keeps, and Ro for potentially failing to adequately warn patients about finasteride’s serious risks before prescribing it online. These platforms made it extremely easy for young men to get finasteride prescriptions for hair loss — often through brief questionnaires rather than thorough medical consultations. The concern is not that telehealth itself is flawed, but that the speed and convenience of these platforms may have bypassed the kind of detailed informed consent discussion that a prescribing decision like this requires.
When a 25-year-old fills out a form online and receives finasteride in the mail days later, there may not have been a meaningful conversation about suicidal ideation, persistent sexual dysfunction, or the one-third chance that new erectile dysfunction could continue long after stopping the drug. The gap between what the FDA label now says and what patients are actually being told is the core of these investigations. For caregivers and family members, this is a reminder to ask loved ones — particularly younger men — whether they are taking finasteride, even if it was not prescribed through a traditional doctor visit. Medications obtained through telehealth platforms may not appear in a patient’s primary care records, creating a blind spot in their medical history.
Legal Fallout and What It Signals About the Drug’s Risk Profile
The legal landscape around finasteride provides additional context. Over 1,000 plaintiffs filed Propecia lawsuits alleging they were not adequately warned about the drug’s risks, with approximately $4.3 million settled out of court. Separately, the consumer advocacy group Public Citizen sued the FDA itself for inaction on adding stronger warnings about suicide risk to finasteride’s label — a rare step that underscores how seriously outside watchdogs viewed the agency’s delay.
While lawsuit settlements do not prove a drug is dangerous — manufacturers often settle to avoid litigation costs — the volume and nature of these claims reflect a pattern of patients who felt blindsided by side effects they were never told to expect. In April 2025, the FDA published a notice documenting 32 adverse drug reactions reported for topical finasteride between 2019 and 2024, including impaired sexual function, anxiety, suicidal thoughts, depression, fatigue, and sleep disturbances. The fact that even topical formulations are generating adverse reports suggests the risks may extend beyond oral dosing.
Where the Science and Regulation Are Heading
The trajectory points toward stricter prescribing standards and better patient education, not toward pulling these drugs from the market. 5-ARIs remain useful medications for specific clinical scenarios, but the era of prescribing them casually — particularly for cosmetic indications — appears to be ending. Israel’s Ministry of Health issued its own finasteride warning in August 2025, and the international regulatory trend is toward greater caution.
For the brain health and dementia care community, this story is a case study in why medication reviews matter. Any drug that can cause depression, cognitive changes, and neuropsychiatric symptoms deserves extra scrutiny in patients who are already at risk for or living with cognitive decline. Advocating for thorough medication reconciliation — asking what every pill does, why it was prescribed, and whether the risk-benefit ratio still makes sense — is one of the most impactful things a caregiver can do.
Conclusion
Finasteride and dutasteride remain available and, for some patients, clinically appropriate. But the weight of evidence — FDA label changes citing suicidal ideation, persistent post-drug sexual dysfunction in a third of affected men, compromised cancer screening, and ongoing investigations into inadequate telehealth prescribing — has fundamentally changed how responsible physicians approach these medications. The days of treating 5-ARIs as a low-risk default are over.
If you or someone you care for is taking a 5-alpha reductase inhibitor, the single most important step is a candid conversation with a prescribing physician about whether the benefits still justify the now well-documented risks. For those in the dementia care space, be especially alert to mood and cognitive changes that could be medication-related rather than disease-related. Stopping a drug is sometimes the most important medical intervention available.
Frequently Asked Questions
What is finasteride, and why is it prescribed?
Finasteride is a 5-alpha reductase inhibitor that blocks conversion of testosterone to DHT. At 5mg (Proscar), it treats enlarged prostate. At 1mg (Propecia), it treats male pattern hair loss. Dutasteride (Avodart) is a related drug in the same class.
What is Post-Finasteride Syndrome?
PFS refers to persistent sexual dysfunction and neuropsychiatric symptoms — including depression, anxiety, and cognitive difficulties — that continue after a patient stops taking finasteride. Research shows one-third of men who developed erectile dysfunction on the drug still had it more than 90 days after discontinuation.
Does finasteride cause suicidal thoughts?
The FDA added suicidal ideation and behavior to finasteride’s label in August 2022. Adverse event data show a reported odds ratio of 34.64 for suicidality in 2022, and a Hebrew University study confirmed significantly higher rates of depressive symptoms in users. Young men ages 18–44 appear to be at elevated risk.
Can finasteride affect prostate cancer screening?
Yes. 5-ARIs cause approximately a 50% drop in PSA levels, which can mask prostate cancer during routine screening. Doctors must adjust PSA interpretation for patients on these drugs.
Should I stop taking finasteride immediately if I am concerned?
Do not stop any medication without consulting your doctor. However, bring your concerns to your next appointment, and report any new depression, anxiety, sexual dysfunction, or cognitive changes right away.
Are telehealth prescriptions for finasteride safe?
Investigations are ongoing into whether telehealth platforms like Hims, Keeps, and Ro adequately inform patients of finasteride’s risks. If you received a prescription online, review the current FDA labeling and discuss the risks with a physician who can evaluate your full medical history.
